Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D2.114 - Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure
D2.115 - Occupational asthma and rhinitis to isocyanates in industrial settings
D2.108 - Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents
D2.110 - Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study
D2.113 - Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF25–75 Levels
D2.120 - Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update
D2.121 - Seroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment
D2.507 - School dust Streptomyces and Mycobacterium exposure and respiratory health in European children: the SINPHONIE study
D2.508 - Climate Change, Allergic Diseases, and Mental Health in Outdoor Workers: A Transdisciplinary Perspective from CliMent COST Action
D2.509 - Do macrophages modulate the response of injured bronchial epithelium after PM2.5 and microplastic exposure?
D2.511 - Beyond PFAS: Atypical oral manifestation of eosinophilic esophagitis in a patient with birch allergy. Case Description
D2.514 - Breathing zone pollen and fungal spore monitoring with an IOM Personal Sampler: A pilot study
D2.515 - Symptom forecasting for birch and grass pollen allergy: the #berlinbreathing project
D2.517 - #berlinbreathing : An app-based citizen science project for pollen allergies
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut
D3.448 - Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study
Download the app
The congress at your fingertips
Available on
Download